Russian Firm Invests $80M in Pakistan Insulin Production

Russian & Pakistan – (Web Desk) – A Russian pharmaceutical company, Zavod Medsintez LLC, along with its Pakistani partner, Genetics Pharmaceuticals Private Limited, has announced an exciting plan to invest around $80 million in Pakistan’s healthcare sector over the next six years. Their goal? To begin producing insulin right here in Pakistan — a move that could make a real difference for millions of people managing diabetes across the country.

The two companies plan to set up an aseptic filling plant and a dedicated insulin manufacturing facility in two phases. The first phase is expected to wrap up by December 2028, with the second following by December 2031.

As part of this development, Pakistan’s Drug Regulatory Authority (DRAP) has already given the green light for three Russian insulin products — Rosinsulin R, Rosinsulin C, and Rosinsulin M 30/70 — to be sold in the local market. Prices will range from approximately Rs1,399 ($5) for a 10ml vial to Rs3,235 ($11.60) for a pack of five cartridges, making them reasonably accessible for patients.

This investment comes at a much-needed time for Pakistan. Prime Minister Shehbaz Sharif’s government has been actively working to attract foreign investment to the country, which is home to over 240 million people. Unfortunately, foreign direct investment has taken a hit lately, dropping by more than 33 percent to just $1.19 billion during the July–February period of the current fiscal year, according to State Bank of Pakistan data. This fresh commitment from Russia is therefore a welcome sign for the country’s economic outlook.

The DRAP made the notified prices conditional and said the price revision is granted on the explicit understanding that Zavod Medsintez and Genetics Pharmaceuticals would “immediately” start the establishment of the relevant manufacturing facility plant and commencement of local production of Active Pharmaceutical Ingredient (API) in two stages.

Russian firm and its local partner plan $80m investment in Pakistan’s pharmaceutical sector over the next six years to start producing insulin locally. https://t.co/6cmX47zjY4

— Arab News Pakistan (@arabnewspk) March 31, 2026

API is the essential, biologically active component within a drug responsible for producing the intended health effects, such as curing, treating, or preventing diseases.

“The first stage is the construction of an aseptic filling plant” at approximately $20 million, it said. The construction of the unit for bulk import and dedicated biological unit for aseptic filling of insulin and its derivatives should be completed by Dec. 31, 2028, the regulator said.

“The second stage is the construction of an API production plant (at) approximately $60 million,” it added.

IMF pushes Pakistan for higher taxes and expanded GST measures

The project will also include development and transfer of technology for the production of biotechnological products (insulins) from the API, i.e., from purification of API to packaging of its finished form, C Biotech, and should be completed by Dec. 31, 2031, the authority said, adding it would monitor progress and require the company to share stage-wise detailed timelines for investment.

“In case of non-compliance with the commitment of setting up manufacturing facility and manufacturing in Pakistan, the product registration shall be canceled,” the DRAP warned.